EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinically Explainable Prediction of Immunotherapy Response Integrating Radiomics and Clinico-Pathological Information in Non-Small Cell Lung Cancer

Jhimli Mitra iD, Soumya Ghose iD, Rajat Thawani iD

Cancers · 18.08.2025 · 17 (16) · 2679

DOI: 10.3390/cancers17162679 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 18.08.2025. Verfasst von Jhimli Mitra und 2 weiteren Autor:innen. Beteiligte Einrichtung: GE HealthCare, Niskayuna, NY 12309, USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Immunotherapy is a viable therapeutic approach for non-small cell lung cancer (NSCLC). Despite the significant survival benefit of immune checkpoint inhibitors PD-1/PD-L1, on average; the objective response rate is around 20% as monotherapy and around 50% in combination with chemotherapy. While PD-L1 IHC is used as a predictive biomarker, its accuracy is subpar.

Methods

In this work, we develop a machine learning (ML) method to predict response to immunotherapy in NSCLC from multimodal clinicopathological biomarkers, tumor and peritumoral radiomic biomarkers from CT images. We further learn a graph structure to understand the associations between biomarkers and treatment response. The graph is then used to create sentences with clinical hypotheses that are finally used in a Large Language Model (LLM) that explains the treatment response predicated on the biomarkers that are comprehensible to clinicians. From a retrospective study, a training dataset of NSCLC with n = 248 tumors from 140 subjects was used for feature selection, ML model training, learning the graph structure, and fine-tuning LLM.

Results

An AUC = 0.83 was achieved for prediction of treatment response on a separate test dataset of n = 84 tumors from 47 subjects.

Conclusions

Our study therefore not only improves the prediction of immunotherapy response in patients with NSCLC from multimodal data but also assists the clinicians in making clinically interpretable predictions by providing language-based explanations.

Schlagwörter

Stichwörter der Autor:innen

clinical explanationimmunotherapy responselarge-language modelmachine learningmultimodal analysisnon-small cell lung cancerradiomics

Autor:innen und Institutionen

  • GE HealthCare, Niskayuna, NY 12309, USA.
  • Division of Hematology and Oncology, Knight Cancer Institute, Oregon Health & Science University (OHSU), Portland, OR 97239, USA.

ORCID-Profile: Jhimli Mitra, Soumya Ghose, Rajat Thawani

Zitieren

APA

Mitra, J., Ghose, S., & Thawani, R. (2025). Clinically Explainable Prediction of Immunotherapy Response Integrating Radiomics and Clinico-Pathological Information in Non-Small Cell Lung Cancer. Cancers, 17(16), 2679. https://doi.org/10.3390/cancers17162679

Vancouver

Mitra J, Ghose S, Thawani R. Clinically Explainable Prediction of Immunotherapy Response Integrating Radiomics and Clinico-Pathological Information in Non-Small Cell Lung Cancer. Cancers. 2025;17(16):2679. doi:10.3390/cancers17162679

BibTeX
@article{Mitra2025,
  author = {Mitra, Jhimli and Ghose, Soumya and Thawani, Rajat},
  title = {Clinically Explainable Prediction of Immunotherapy Response Integrating Radiomics and Clinico-Pathological Information in Non-Small Cell Lung Cancer},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {16},
  pages = {2679},
  doi = {10.3390/cancers17162679}
}
Kostenlos starten →